In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Corbus Pharmaceuticals (CRBP), with a price target of $24. The company’s shares closed yesterday at $6.85.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.2% and a 40.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $26.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.96 and a one-year low of $4.50. Currently, Corbus Pharmaceuticals has an average volume of 849.2K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBP in relation to earlier this year. Most recently, in November 2018, Mark Tepper, the President and CSO of CRBP bought 10,000 shares for a total of $10,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
